HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

HAIXI PHARMA

200.000

+6.1003.15%

Volume:71.45K

Turnover:14.28M

Market Cap:15.74B

PE:67.22

High:204.000

Open:196.400

Low:194.400

Close:193.900

52wk High:302.400

52wk Low:97.500

Shares:78.71M

HK Float Shares:78.71M

Volume Ratio:0.40

T/O Rate:0.09%

Dividend:- -

Dividend Rate:- -

EPS(LYR):2.975

ROE:16.58%

ROA:9.23%

PB:8.47

PE(LYR):67.22

PS:23.17

Loading ...

Overview Company News Filings

Fujian Haixi Pharmaceuticals Announces First Extraordinary General Meeting

HAIXI PHARMA announces board reshuffle: Non-Executive Director Wang Xinkun resigns; Chen Tingze nominated as Executive Director

Bulletin Express

Fujian Haixi Pharmaceuticals Co - Nominates Chen Tingze as Candidate for Executive Director

THOMSON REUTERS

Fujian Haixi Pharmaceuticals Plans Auditor Switch to RSM China from Deloitte

Fujian Haixi Pharmaceuticals Gets China Nod for Glioblastoma Drug Trial

MT Newswires Live

HAIXI PHARMA secures NMPA IND approval for next-generation glioblastoma candidate HXP089

Bulletin Express

HAIXI PHARMA's HXP089 Project Receives NMPA Approval for Glioblastoma Clinical Trial Application

Fujian Haixi Pharma Says China NMPA Clears Hxp089 IND for Glioblastoma Trial

Fujian Haixi Pharmaceuticals Co - Nmpa Approves Ind Application for Hxp089 for Glioblastoma

THOMSON REUTERS

Fujian Haixi Pharma Begins Phase III Trial of Osteosarcoma Drug

MT Newswires Live

HAIXI PHARMA Records 2.01 Billion HKD in Deposited Securities, Major Shareholder Transfers Shares to CMB International

HAIXI PHARMA Initiates Phase III Trial for C019199 Tablets in Osteosarcoma

Haixi Pharmaceuticals Launches Phase III Trial of First-in-Class C019199 Tablets for Refractory Osteosarcoma

Bulletin Express

Haixi Pharmaceuticals Launches Phase III Trial of C019199 Tablet in Osteosarcoma

Fujian Haixi Pharmaceuticals Co - Launches Phase Iii Clinical Trial of C019199 Tablets for Osteosarcoma

THOMSON REUTERS

Hong Kong Innovative Drug Stocks Jump With HAIXI PHARMA and INNOCARE up 7%; KEYMED up 5%, REMEGEN up 4%

Tiger Newspress

HAIXI PHARMA Shareholders Deposit Nearly 10 Million Shares with CMB International Securities

CMB International Initiates Coverage on Haixi Pharma with 'Buy' Rating and HK$280 Target

HAIXI PHARMA Finalises New Articles of Association to Support Upcoming H-Share Listing and Strengthen Governance

Bulletin Express

HAIXI PHARMA Releases Updated Board Procedure Rules to Strengthen Governance Framework

Bulletin Express

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/stock/02637/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"02637","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02637\",,,,,undefined,":{"symbol":"02637","market":"HK","secType":"STK","nameCN":"HAIXI PHARMA","latestPrice":200,"timestamp":1787645292993,"preClose":193.9,"halted":0,"volume":71450,"delay":0,"changeRate":0.03145951521402782,"floatShares":78707270,"shares":78707270,"eps":2.9752598410384232,"marketStatus":"Not Yet Opened","change":6.1,"latestTime":"08-25 16:08:12","open":196.4,"high":204,"low":194.4,"amount":14283540,"amplitude":0.04951,"askPrice":200,"askSize":150,"bidPrice":199.7,"bidSize":150,"shortable":3,"etf":0,"ttmEps":2.905253727131637,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787707800000},"marketStatusCode":0,"adr":0,"listingDate":1760889600000,"exchange":"SEHK","adjPreClose":193.9,"openAndCloseTimeList":[[1787621400000,1787630400000],[1787634000000,1787644800000]],"volumeRatio":0.3994074571635207,"lotSize":50,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02637\",,,,,undefined,":{"symbol":"02637","floatShares":78707270,"roa":"9.23%","roe":"16.58%","lyrEps":2.97526,"volumeRatio":0.3994074571635207,"shares":78707270,"dividePrice":0,"high":204,"amplitude":0.04951,"preClose":193.9,"low":194.4,"week52Low":97.5,"pbRate":"8.47","psRate":"23.17","week52High":302.4,"institutionHeld":0,"latestPrice":200,"eps":2.9752598410384232,"divideRate":0,"volume":71450,"delay":0,"ttmEps":2.905253727131637,"open":196.4,"prevYearClose":136,"prevWeekClose":201,"prevMonthClose":171,"prevQuarterClose":180,"fiveDayClose":217,"twentyDayClose":171,"sixtyDayClose":223.8,"earningDate":1787846400000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02637\",params:#limit:5,,,undefined,":[{"date":"2026-08-28","symbol":"02637","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787880600000,"name":null,"time":"","dateTimestamp":1787846400000,"actualEps":null},{"date":"2026-03-30","symbol":"02637","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774834200000,"name":null,"time":"","dateTimestamp":1774800000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02637\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02637\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1781107200000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02637\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02637","date":"2026-08-24","current":68.833095,"percent":0.601942,"low":41.43616,"twenty":68.34426,"median":72.080642,"eighty":79.10615,"high":108.687128,"avg":73.777734,"sd":9.144984,"marketCap":15261339653},"quantilePoints":[{"date":"2025-10-16","current":41.43616,"twenty":41.43616,"median":41.43616,"eighty":41.43616,"marketCap":6150186077},{"date":"2025-10-24","current":58.044665,"twenty":53.788314,"median":54.742854,"eighty":58.044665,"marketCap":8618446065},{"date":"2025-10-31","current":63.409996,"twenty":54.11413,"median":58.177187,"eighty":60.582738,"marketCap":9429130946},{"date":"2025-11-07","current":65.038519,"twenty":55.071217,"median":59.875924,"eighty":63.533346,"marketCap":9665252756},{"date":"2025-11-14","current":69.713569,"twenty":57.493757,"median":61.562796,"eighty":68.778725,"marketCap":10389359640},{"date":"2025-11-21","current":66.575785,"twenty":58.2567,"median":64.026746,"eighty":69.208194,"marketCap":9917116020},{"date":"2025-11-28","current":68.072175,"twenty":59.478322,"median":65.807152,"eighty":68.767812,"marketCap":10176850011},{"date":"2025-12-05","current":68.42835,"twenty":59.854834,"median":66.893861,"eighty":68.767812,"marketCap":10247686554},{"date":"2025-12-12","current":69.403659,"twenty":60.326406,"median":67.279459,"eighty":69.361692,"marketCap":10412971821},{"date":"2025-12-19","current":69.502155,"twenty":61.237436,"median":67.861589,"eighty":69.423358,"marketCap":10452325456},{"date":"2025-12-24","current":72.521094,"twenty":61.537644,"median":68.055113,"eighty":69.462757,"marketCap":10940310530},{"date":"2026-01-02","current":68.547,"twenty":62.032842,"median":68.254334,"eighty":69.697511,"marketCap":10381488913},{"date":"2026-01-09","current":76.256401,"twenty":63.533346,"median":68.54394,"eighty":70.33117,"marketCap":11577839417},{"date":"2026-01-16","current":83.450154,"twenty":64.030428,"median":68.594109,"eighty":71.180851,"marketCap":12711224105},{"date":"2026-01-23","current":75.203122,"twenty":64.243828,"median":68.851274,"eighty":73.407226,"marketCap":11444037058},{"date":"2026-01-30","current":72.029156,"twenty":65.345972,"median":69.26967,"eighty":73.580372,"marketCap":11011147073},{"date":"2026-02-06","current":69.741329,"twenty":66.631937,"median":69.18814,"eighty":73.524909,"marketCap":10688447266},{"date":"2026-02-13","current":69.700471,"twenty":66.864009,"median":69.376262,"eighty":73.289662,"marketCap":10743542355},{"date":"2026-02-20","current":69.085102,"twenty":66.878935,"median":69.376262,"eighty":72.984771,"marketCap":10633352177},{"date":"2026-02-27","current":72.331605,"twenty":67.046254,"median":69.403659,"eighty":72.584608,"marketCap":11255139610},{"date":"2026-03-06","current":63.89376,"twenty":67.046254,"median":69.448144,"eighty":72.584608,"marketCap":9862020931},{"date":"2026-03-13","current":75.4784,"twenty":67.193436,"median":69.633279,"eighty":73.562991,"marketCap":11703771049},{"date":"2026-03-20","current":69.956787,"twenty":67.26348,"median":69.715081,"eighty":73.483508,"marketCap":10806508171},{"date":"2026-03-27","current":78.768036,"twenty":67.31702,"median":69.741329,"eighty":73.616705,"marketCap":12136661034},{"date":"2026-04-02","current":69.050489,"twenty":67.448055,"median":69.756887,"eighty":73.953025,"marketCap":13907574609},{"date":"2026-04-10","current":75.734842,"twenty":67.617502,"median":69.89051,"eighty":74.51958,"marketCap":15371529831},{"date":"2026-04-17","current":75.664292,"twenty":67.861589,"median":70.029272,"eighty":74.51958,"marketCap":15363659104},{"date":"2026-04-24","current":92.094347,"twenty":68.038051,"median":70.361759,"eighty":74.892793,"marketCap":18700847352},{"date":"2026-04-30","current":101.138303,"twenty":68.06535,"median":70.518529,"eighty":75.515578,"marketCap":20542597470},{"date":"2026-05-08","current":91.134409,"twenty":68.133872,"median":70.614497,"eighty":76.472636,"marketCap":18574915720},{"date":"2026-05-15","current":84.578883,"twenty":68.178204,"median":70.813553,"eighty":78.193464,"marketCap":17284116492},{"date":"2026-05-22","current":93.496946,"twenty":68.295676,"median":71.108793,"eighty":80.407586,"marketCap":19062900794},{"date":"2026-05-29","current":86.09458,"twenty":68.386305,"median":71.340959,"eighty":80.936301,"marketCap":17614687026},{"date":"2026-06-05","current":72.717092,"twenty":68.497704,"median":72.103769,"eighty":80.766638,"marketCap":14899286211},{"date":"2026-06-12","current":67.961351,"twenty":68.497704,"median":71.340959,"eighty":80.580489,"marketCap":13915445336},{"date":"2026-06-18","current":66.149737,"twenty":68.365282,"median":71.108793,"eighty":80.547429,"marketCap":13577004075},{"date":"2026-06-26","current":64.123676,"twenty":68.103023,"median":70.813553,"eighty":80.470686,"marketCap":13096889728},{"date":"2026-07-03","current":76.78307,"twenty":68.156523,"median":70.813553,"eighty":80.277662,"marketCap":15694229638},{"date":"2026-07-10","current":79.190679,"twenty":68.212992,"median":71.108793,"eighty":80.277662,"marketCap":16166473258},{"date":"2026-07-17","current":71.84101,"twenty":68.34426,"median":71.590985,"eighty":79.86919,"marketCap":14718259490},{"date":"2026-07-24","current":70.518964,"twenty":68.451468,"median":71.287767,"eighty":79.796901,"marketCap":14450654772},{"date":"2026-07-31","current":65.554893,"twenty":68.149296,"median":70.906272,"eighty":79.747346,"marketCap":13458943170},{"date":"2026-08-07","current":75.261161,"twenty":68.149296,"median":71.19828,"eighty":79.190679,"marketCap":15481720009},{"date":"2026-08-14","current":78.261297,"twenty":68.185431,"median":71.340959,"eighty":78.768036,"marketCap":16119248896},{"date":"2026-08-21","current":76.639812,"twenty":68.323237,"median":72.054899,"eighty":79.190679,"marketCap":15820161270},{"date":"2026-08-24","current":73.959257,"twenty":68.34426,"median":72.080642,"eighty":79.10615,"marketCap":15261339653}],"updateTime":1787681582477},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02637\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2651452644","title":"Fujian Haixi Pharmaceuticals Announces First Extraordinary General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2651452644","media":"Reuters","labels":["conferences","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651452644?lang=en_us&edition=fundamental","pubTime":"2026-07-15 18:43","pubTimestamp":1784112224,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals announces first extraordinary general meetingFujian Haixi Pharmaceuticals will hold a first extraordinary general meeting in Fuzhou, China on Aug. 4, 2026.Shareholders wil","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nNDL7wllK0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176589941","title":"HAIXI PHARMA announces board reshuffle: Non-Executive Director Wang Xinkun resigns; Chen Tingze nominated as Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=1176589941","media":"Bulletin Express","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176589941?lang=en_us&edition=fundamental","pubTime":"2026-07-15 18:41","pubTimestamp":1784112119,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals Co., Ltd. (“HAIXI PHARMA”) reported that Non-Executive Director Wang Xinkun will step down once shareholders elect a replacement at an upcoming general meeting. The...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651454014","title":"Fujian Haixi Pharmaceuticals Co - Nominates Chen Tingze as Candidate for Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2651454014","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651454014?lang=en_us&edition=fundamental","pubTime":"2026-07-15 18:35","pubTimestamp":1784111752,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nFWN43H052:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651745403","title":"Fujian Haixi Pharmaceuticals Plans Auditor Switch to RSM China from Deloitte","url":"https://stock-news.laohu8.com/highlight/detail?id=2651745403","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651745403?lang=en_us&edition=fundamental","pubTime":"2026-07-15 18:33","pubTimestamp":1784111625,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals plans auditor switch to RSM China from DeloitteFujian Haixi Pharmaceuticals will switch financial reporting to China Accounting Standards for Business Enterprises from its","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nNDL4SPz0X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651293174","title":"Fujian Haixi Pharmaceuticals Gets China Nod for Glioblastoma Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2651293174","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651293174?lang=en_us&edition=fundamental","pubTime":"2026-07-14 18:20","pubTimestamp":1784024435,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals (HKG:2637) obtained approval for an investigational new drug application for a clinical trial of HXP089.The drug has been developed by the company to treat glioblastoma, according to a Tuesday Hong Kong bourse filing.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142109509","title":"HAIXI PHARMA secures NMPA IND approval for next-generation glioblastoma candidate HXP089","url":"https://stock-news.laohu8.com/highlight/detail?id=1142109509","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142109509?lang=en_us&edition=fundamental","pubTime":"2026-07-14 17:20","pubTimestamp":1784020849,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals Co., Ltd. (HAIXI PHARMA) has received Investigational New Drug (IND) approval from China’s National Medical Products Administration (NMPA) for HXP089, a selective...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116749786","title":"HAIXI PHARMA's HXP089 Project Receives NMPA Approval for Glioblastoma Clinical Trial Application","url":"https://stock-news.laohu8.com/highlight/detail?id=1116749786","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116749786?lang=en_us&edition=fundamental","pubTime":"2026-07-14 17:13","pubTimestamp":1784020411,"startTime":"0","endTime":"0","summary":"The company's self-developed HXP089 project, intended for the treatment of glioblastoma (GBM), has received approval for its Investigational New Drug (IND) application from the Center for Drug...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMED","IND","BK1191","02637","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651176958","title":"Fujian Haixi Pharma Says China NMPA Clears Hxp089 IND for Glioblastoma Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2651176958","media":"Reuters","labels":["productRelease","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651176958?lang=en_us&edition=fundamental","pubTime":"2026-07-14 17:08","pubTimestamp":1784020117,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharma says China NMPA clears HXP089 IND for glioblastoma trialFujian Haixi Pharmaceuticals secured NMPA clearance for an IND for HXP089 in glioblastoma, enabling clinical trials in China","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260714:nNDL59l4vF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Fujian Haixi Pharma Says China NMPA Clears Hxp089 IND for Glioblastoma Trial","news_tag":"productRelease,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651769371","title":"Fujian Haixi Pharmaceuticals Co - Nmpa Approves Ind Application for Hxp089 for Glioblastoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2651769371","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651769371?lang=en_us&edition=fundamental","pubTime":"2026-07-14 17:08","pubTimestamp":1784020083,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260714:nFWN43G0ES:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650118498","title":"Fujian Haixi Pharma Begins Phase III Trial of Osteosarcoma Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2650118498","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650118498?lang=en_us&edition=fundamental","pubTime":"2026-07-10 18:40","pubTimestamp":1783680005,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals  officially began a phase III clinical trial of the C019199 tablets, according to a Friday Hong Kong bourse filing.The trial aims to evaluate the efficacy and safety of the drug for the treatment of osteosarcoma after the failure of at least two prior lines of therapy.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["III","BK1191","BK4134","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152440435","title":"HAIXI PHARMA Records 2.01 Billion HKD in Deposited Securities, Major Shareholder Transfers Shares to CMB International","url":"https://stock-news.laohu8.com/highlight/detail?id=1152440435","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152440435?lang=en_us&edition=fundamental","pubTime":"2026-07-10 09:02","pubTimestamp":1783645348,"startTime":"0","endTime":"0","summary":"According to the latest data from the Hong Kong Stock Exchange, a significant position change occurred for HAIXI PHARMA (02637) on July 9th. The total value of securities deposited reached 2.013...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["161027","02637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170255563","title":"HAIXI PHARMA Initiates Phase III Trial for C019199 Tablets in Osteosarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=1170255563","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170255563?lang=en_us&edition=fundamental","pubTime":"2026-07-09 16:42","pubTimestamp":1783586555,"startTime":"0","endTime":"0","summary":"HAIXI PHARMA (ASX: 02637) has announced the official commencement of a Phase III clinical trial (CTR20261818) for its self-developed C019199 tablets, targeting osteosarcoma patients who have failed...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637","IBBQ","BMED","III","BK1191","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104564655","title":"Haixi Pharmaceuticals Launches Phase III Trial of First-in-Class C019199 Tablets for Refractory Osteosarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=1104564655","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104564655?lang=en_us&edition=fundamental","pubTime":"2026-07-09 16:40","pubTimestamp":1783586437,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals Co., Ltd. (Haixi Pharmaceuticals) has formally commenced a multicenter, randomized, controlled, open-label Phase III clinical study (Protocol HXP019-CTPIII-02) to...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650384947","title":"Haixi Pharmaceuticals Launches Phase III Trial of C019199 Tablet in Osteosarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2650384947","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650384947?lang=en_us&edition=fundamental","pubTime":"2026-07-09 16:37","pubTimestamp":1783586240,"startTime":"0","endTime":"0","summary":"Haixi Pharmaceuticals launches Phase III trial of C019199 tablet in osteosarcomaFujian Haixi Pharmaceuticals initiated a Phase III trial of C019199 tablets in osteosarcoma patients who failed at least","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260709:nNDLbnNnVb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650394782","title":"Fujian Haixi Pharmaceuticals Co - Launches Phase Iii Clinical Trial of C019199 Tablets for Osteosarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2650394782","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650394782?lang=en_us&edition=fundamental","pubTime":"2026-07-09 16:36","pubTimestamp":1783586169,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260709:nFWN43B0JO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149233574","title":"Hong Kong Innovative Drug Stocks Jump With HAIXI PHARMA and INNOCARE up 7%; KEYMED up 5%, REMEGEN up 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1149233574","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149233574?lang=en_us&edition=fundamental","pubTime":"2026-07-06 09:58","pubTimestamp":1783303082,"startTime":"0","endTime":"0","summary":"Hong Kong innovative drug stocks jumped in market trading. $HAIXI PHARMA(02637)$, $INNOCARE(09969)$ up 7%; $KEYMED BIO-B(02162)$ up 5%; $REMEGEN(09995)$, $INNOVENT BIO(01801)$, $SIMCERE PHARMA(02096)$ up 4%; $LEPU BIO(02157)$ up 3%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SOXL","02096","01801","02157","02162","02637","09969","09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168595480","title":"HAIXI PHARMA Shareholders Deposit Nearly 10 Million Shares with CMB International Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=1168595480","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168595480?lang=en_us&edition=fundamental","pubTime":"2026-06-22 09:07","pubTimestamp":1782090453,"startTime":"0","endTime":"0","summary":"According to the latest data from the Hong Kong Stock Exchange, a significant change in shareholding for HAIXI PHARMA (02637) was recorded on June 18th.The total value of shares held in the relevant...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637","BK1191","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154998341","title":"CMB International Initiates Coverage on Haixi Pharma with 'Buy' Rating and HK$280 Target","url":"https://stock-news.laohu8.com/highlight/detail?id=1154998341","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154998341?lang=en_us&edition=fundamental","pubTime":"2026-06-10 11:08","pubTimestamp":1781060902,"startTime":"0","endTime":"0","summary":"CMB International has released a research report initiating coverage on HAIXI PHARMA (02637), assigning a 'Buy' rating and setting a target price of HK$280.The report describes HAIXI PHARMA as an...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EWH","02637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148278143","title":"HAIXI PHARMA Finalises New Articles of Association to Support Upcoming H-Share Listing and Strengthen Governance","url":"https://stock-news.laohu8.com/highlight/detail?id=1148278143","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148278143?lang=en_us&edition=fundamental","pubTime":"2026-05-27 17:44","pubTimestamp":1779875063,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals Co., Ltd. (“HAIXI PHARMA”) has released its amended Articles of Association, effective upon the planned listing of its H shares on the Stock Exchange of Hong Kong. Key...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146241795","title":"HAIXI PHARMA Releases Updated Board Procedure Rules to Strengthen Governance Framework","url":"https://stock-news.laohu8.com/highlight/detail?id=1146241795","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146241795?lang=en_us&edition=fundamental","pubTime":"2026-05-27 17:43","pubTimestamp":1779875038,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals Co., Ltd. (HAIXI PHARMA) has published the “Rules of Procedure for Meeting of the Board of Directors”, a comprehensive governance document intended to standardise...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":79,"code":"91000000","status":"200"}]}}